Cardiovalve

Cardiovalve is a pioneering medical device company that is focused on developing a transfemoral mitral valve replacement system. The company's slogan, "Pioneering a new era in mitral valve replacement with a transfemoral delivery system designed for enhanced safety and minimal cardiac interference," aptly captures its innovative approach. Specifically, the Cardiovalve system is meticulously crafted to replace the mitral valve via a transfemoral technique, utilizing femoral venous access. This method offers several notable advantages, including a compact profile that minimizes intrusion into the left ventricle, thereby reducing disruption to cardiac blood flow and enhancing safety. Founded in 2017, Cardiovalve operates within the Biotechnology, Health Care, and Medical Devices industries. Currently, the company is engaging in clinical studies to assess the safety and performance of its system, with plans to seek approval in the EU and US. Although specific details regarding the company's headquartered location and its last investment are not available at this time, Cardiovalve's focused dedication to advancing cardiovascular treatment through innovative medical devices positions it as a promising venture for potential investors seeking opportunities within the medical technology sector.